Enliven Therapeutics, Inc.
Total Trades
203
Buys
1
Sells
139
Largest Trade
$1M+
Insiders
9
Institutional Funds
94
Inst. Value
$1M+
Activist Filings
38
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $50K–$100K | 3K | $27.56 | Aug 2, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $50K–$100K | 2K | $27.56 | Aug 2, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $15K–$50K | 991 | $27.53 | Aug 2, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 991 | $2.48 | Aug 2, 2024 |
| Heyman Richard A. | Director | SELL | $50K–$100K | 2K | $27.50 | Aug 2, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 12K | $26.70 | Jul 31, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $100K–$500K | 5K | $26.68 | Jul 31, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 5K | $2.48 | Jul 31, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 12K | $22.89 | Jul 3, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 4K | $2.48 | Jul 2, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 4K | $22.57 | Jul 2, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 12K | $21.66 | Jun 27, 2024 |
| Heyman Richard A. | Director | SELL | $15K–$50K | 1K | $21.48 | Jun 20, 2024 |
| Patel Anish | CHIEF OPERATING OF… | EXERCISE | $1K–$15K | 1K | $2.48 | Jun 10, 2024 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $15K–$50K | 1K | $20.06 | Jun 10, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | EXERCISE | $1K–$15K | 12K | $1.12 | May 31, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 12K | $21.73 | May 31, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 12K | $23.18 | May 30, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | EXERCISE | $1K–$15K | 12K | $1.12 | May 30, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 4K | $23.18 | May 30, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 4K | $2.48 | May 30, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | EXERCISE | $1K–$15K | 12K | $1.12 | May 1, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 12K | $17.92 | May 1, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | May 1, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $16.97 | May 1, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | EXERCISE | $1K–$15K | 12K | $1.12 | Apr 29, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 12K | $16.89 | Apr 29, 2024 |
| Patel Anish | CHIEF OPERATING OF… | EXERCISE | $15K–$50K | 15K | $2.48 | Apr 15, 2024 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 18K | $25.03 | Apr 15, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | EXERCISE | $15K–$50K | 30K | $1.12 | Apr 15, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $500K+ | 30K | $25.04 | Apr 15, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $1M+ | 48K | $25.04 | Apr 15, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | EXERCISE | $50K–$100K | 48K | $1.12 | Apr 15, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $15K–$50K | 14K | $2.48 | Apr 15, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $100K–$500K | 14K | $24.72 | Apr 15, 2024 |
| Heyman Richard A. | Director | SELL | $100K–$500K | 7K | $24.11 | Apr 15, 2024 |
| Collins Helen Louise | CHIEF MEDICAL OFFI… | EXERCISE | $15K–$50K | 20K | $2.48 | Apr 15, 2024 |
| Collins Helen Louise | CHIEF MEDICAL OFFI… | SELL | $500K+ | 20K | $25.07 | Apr 15, 2024 |
| Ballal Rahul D. | Director | EXERCISE | $500K+ | 67K | $13.08 | Apr 12, 2024 |
| Ballal Rahul D. | Director | SELL | $1M+ | 67K | $23.36 | Apr 12, 2024 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $50K–$100K | 5K | $18.60 | Apr 11, 2024 |
| Ballal Rahul D. | Director | EXERCISE | $15K–$50K | 3K | $12.60 | Apr 9, 2024 |
| Ballal Rahul D. | Director | SELL | $50K–$100K | 3K | $19.15 | Apr 9, 2024 |
| Ballal Rahul D. | Director | EXERCISE | $15K–$50K | 3K | $5.73 | Apr 4, 2024 |
| Ballal Rahul D. | Director | SELL | $50K–$100K | 3K | $19.08 | Apr 4, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | EXERCISE | $1K–$15K | 12K | $1.12 | Apr 4, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 12K | $18.60 | Apr 4, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $18.25 | Mar 29, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Mar 29, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 12K | $17.56 | Mar 27, 2024 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 94 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| ORBIMED ADVISORS LLC | 8.0M | $1M+ | SH |
| Fairmount Funds Management LLC | 3.7M | $1M+ | SH |
| VR Adviser, LLC | 3.2M | $1M+ | SH |
| Point72 Asset Management, L.P. | 1.5M | $1M+ | SH |
| Novo Holdings A/S | 1.5M | $1M+ | SH |
| Capital Research Global Investors | 1.3M | $1M+ | SH |
| Pictet Asset Management Holding SA | 1.3M | $1M+ | SH |
| STATE STREET CORP | 1.1M | $1M+ | SH |
| Soleus Capital Management, L.P. | 1.0M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 911K | $1M+ | SH |
| 5AM Venture Management, LLC | 772K | $1M+ | SH |
| Candriam S.C.A. | 453K | $1M+ | SH |
| Spruce Street Capital LP | 446K | $1M+ | SH |
| DIMENSIONAL FUND ADVISORS LP | 357K | $1M+ | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 355K | $1M+ | SH |
| Logos Global Management LP | 340K | $1M+ | SH |
| Patient Square Capital LP | 308K | $1M+ | SH |
| VANGUARD GROUP INC | 304K | $1M+ | SH |
| SPHERA FUNDS MANAGEMENT LTD. | 227K | $1M+ | SH |
| Exome Asset Management LLC | 222K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Nov 14, 2025
5.4%
3.2M shares
SC 13G/A · Nov 5, 2025
13.3%
7.9M shares
SC 13G/A · Aug 14, 2025
9.9%
6.0M shares
Fairmount Funds Management LLC
SC 13G/A · Aug 14, 2025
6.3%
3.7M shares
SC 13G · Aug 14, 2025
5.2%
2.5M shares
SC 13G/A · Jul 17, 2025
5.1%
2.9M shares
SC 13D/A · Jun 17, 2025
13.4%
7.9M shares
Fairmount Funds Management LLC
SC 13G/A · Feb 14, 2025
6.6%
3.2M shares
SC 13G/A · Feb 14, 2025
4.9%
2.4M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Nov 14, 2024
8.5%
4.0M shares
SC 13G/A · Nov 14, 2024
2.2%
1.1M shares
SC 13G/A · Nov 14, 2024
3.7%
6 shares
Fairmount Funds Management LLC
SC 13G/A · Nov 14, 2024
6.8%
3.2M shares
SC 13G/A · Nov 14, 2024
8.7%
4.1M shares
SC 13G · Nov 13, 2024
5.7%
2.7M shares
SC 13G · Nov 8, 2024
6.2%
2.9M shares
SC 13G · Oct 24, 2024
6.2%
2.9M shares
SC 13D/A · Jul 29, 2024
4.1%
1.9M shares
SC 13D/A · May 20, 2024
16.8%
7.9M shares
SC 13D/A · Apr 15, 2024
5.1%
2.4M shares
SC 13D/A · Apr 4, 2024
19.2%
9.0M shares
SC 13D/A · Feb 16, 2024
7.8%
3.2M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Feb 15, 2024
7.2%
3.0M shares
SC 13G/A · Feb 14, 2024
0.1%
6 shares
SC 13G/A · Feb 14, 2024
5.7%
6 shares
SC 13G/A · Feb 14, 2024
7.0%
2.9M shares
Fairmount Funds Management LLC
SC 13G/A · Feb 14, 2024
5.2%
2.1M shares
SC 13G/A · Feb 14, 2024
0.9%
389K shares
SC 13D/A · Feb 2, 2024
9.4%
3.9M shares
SC 13D/A · Aug 28, 2023
10.9%
4.5M shares
SC 13G · May 10, 2023
10.7%
4.4M shares
Fairmount Funds Management LLC
SC 13G · Apr 27, 2023
5.2%
2.1M shares
SC 13G · Apr 24, 2023
5.1%
2.1M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G · Mar 13, 2023
5.4%
2.2M shares
SC 13G · Mar 6, 2023
5.6%
6 shares
SC 13D · Mar 6, 2023
11.8%
4.8M shares
SC 13G/A · Feb 28, 2023
3.5%
1.4M shares
SC 13D · Feb 28, 2023
21.8%
8.9M shares